Filtros de búsqueda

Lista de obras de Tina Vilsbøll

A 25-year-old woman with type 2 diabetes and liver disease

artículo científico publicado en 2014

A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges

artículo científico publicado en 2017

A decision support tool for appropriate glucose-lowering therapy in patients with type 2 diabetes

artículo científico publicado en 2014

A sandwich ELISA for measurement of the primary glucagon-like peptide-1 metabolite

artículo científico publicado en 2017

Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes--focus on pancreatitis and pancreas cancer

artículo científico publicado en 2014

Alcohol consumption among patients with diabetes: a survey-based cross-sectional study of Danish adults with diabetes

artículo científico publicado en 2016

Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis

artículo científico publicado en 2016

Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects

artículo científico publicado en 2003

Cardiovascular biomarkers in clinical studies of type 2 diabetes

artículo científico publicado en 2018

Cardiovascular safety and benefits of GLP-1 receptor agonists

artículo científico publicado en 2017

Cephalic phase secretion of insulin and other enteropancreatic hormones in humans

artículo científico publicado en 2015

Characterisation of oral and i.v. glucose handling in truncally vagotomised subjects with pyloroplasty

artículo científico publicado en 2013

Cholecystokinin-Induced Gallbladder Emptying and Metformin Elicit Additive Glucagon-Like Peptide-1 Responses

artículo científico publicado en 2016

Cholesterol remnants and triglycerides are associated with decreased myocardial function in patients with type 2 diabetes

artículo científico publicado en 2016

Circulating Glucagon 1-61 Regulates Blood Glucose by Increasing Insulin Secretion and Hepatic Glucose Production

artículo científico publicado en 2017

Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes

artículo científico publicado en 2020

Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira).

artículo científico publicado en 2014

Cross-sectoral collaboration in type 2 diabetes management in Denmark ⬇️

artículo científico publicado en 2018

Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial

artículo científico publicado en 2019

Determinants of Fasting Hyperglucagonemia in Patients with Type 2 Diabetes and Nondiabetic Control Subjects

artículo científico publicado en 2018

Dialysis-Requiring Acute Kidney Injury in Denmark 2000-2012: Time Trends of Incidence and Prevalence of Risk Factors-A Nationwide Study

artículo científico publicado en 2016

Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial

artículo científico publicado en 2014

Does glucagon-like peptide-1 (GLP-1) receptor agonist stimulation reduce alcohol intake in patients with alcohol dependence: study protocol of a randomised, double-blinded, placebo-controlled clinical trial

EFFICACY AND SAFETY OF IDEGLIRA IN OLDER PATIENTS WITH TYPE 2 DIABETES

artículo científico publicado en 2018

Effect of Antibiotics on Gut Microbiota, Gut Hormones and Glucose Metabolism

artículo científico publicado en 2015

Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure

artículo científico publicado en 2015

Effect of Roux-en-Y gastric bypass on the distribution and hormone expression of small-intestinal enteroendocrine cells in obese patients with type 2 diabetes.

artículo científico publicado en 2015

Effect of bile acid sequestrants on glycaemic control: protocol for a systematic review with meta-analysis of randomised controlled trials

artículo científico publicado en 2012

Effect of exercise combined with glucagon-like peptide-1 receptor agonist treatment on cardiac function: A randomized double-blind placebo-controlled clinical trial

artículo científico publicado en 2017

Effect of the EndoBarrier Gastrointestinal Liner on obesity and type 2 diabetes: protocol for systematic review and meta-analysis of clinical studies

artículo científico publicado en 2013

Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study

artículo científico publicado en 2019

Effects of glucagon-like peptide-1 on glucagon secretion in patients with non-alcoholic fatty liver disease

artículo científico publicado en 2015

Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: A narrative review of head-to-head comparisons

artículo científico publicado en 2017

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

artículo científico publicado en 2012

Efficacy and Safety of Glimepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type 3): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA)

artículo científico publicado en 2020

Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add-on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel-design, open-label, Phase 3 trial

scientific article published on 31 January 2020

Efficacy and safety of fixed-ratio combination of insulin degludec and liraglutide (IDegLira) for the treatment of type 2 diabetes

artículo científico publicado en 2017

Emerging GLP-1 receptor agonists

artículo científico publicado en 2011

Enteroendocrine K and L cells in healthy and type 2 diabetic individuals

artículo científico publicado en 2017

Evidence of Extrapancreatic Glucagon Secretion in Man

article

Exenatide: pharmacokinetics, clinical use, and future directions

artículo científico publicado en 2017

Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide

artículo científico

Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin

scientific article published on 08 April 2019

GIP's effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3-30)NH2

scientific article published on 14 October 2019

GIP(3-30)NH2 is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study

artículo científico publicado en 2017

Gastric aspiration therapy is a possible alternative to treatment of obesity ⬇️

artículo científico publicado en 2017

Glucagon-like peptide 1 in health and disease

artículo científico publicado en 2018

Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes

artículo científico publicado en 2017

Glucagon-like peptide-1, glucose homeostasis and diabetes

scientific article published on 18 March 2008

Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes

artículo científico publicado en 2010

Gluco-metabolic effects of oral and intravenous alcohol administration in men

scientific article published on 01 October 2019

Glucose metabolism in patients with psoriasis

artículo científico publicado en 2018

Glucose-Dependent Insulinotropic Polypeptide (GIP) Inhibits Bone Resorption Independently of Insulin and Glycemia

Glucose-Dependent Insulinotropic Polypeptide (GIP) Reduces Bone Resorption in Patients With Type 2 Diabetes

scientific article published on 16 July 2020

Glucose-Dependent Insulinotropic Polypeptide Is a Pancreatic Polypeptide Secretagogue in Humans

artículo científico publicado en 2020

Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes

artículo científico publicado en 2014

Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans

artículo científico publicado en 2014

Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans

artículo científico publicado en 2011

Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes

artículo científico publicado en 2013

Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial

artículo científico publicado en 2014

Glucose-lowering effects and mechanisms of the bile acid-sequestering resin sevelamer.

artículo científico publicado en 2018

Guanylin and uroguanylin mRNA expression is increased following Roux-en-Y gastric bypass, but guanylins do not play a significant role in body weight regulation and glycemic control

artículo científico publicado en 2017

Gut Mucosal Gene Expression and Metabolic Changes After Roux-en-Y Gastric Bypass Surgery

artículo científico publicado en 2020

Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?

artículo científico publicado en 2014

Hyperglucagonemia correlates with plasma levels of non-branched-chain amino acids in patients with liver disease independent of type 2 diabetes

artículo científico publicado en 2017

IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin Therapy

artículo científico publicado en 2015

Impact of type 2 diabetes and duration of type 2 diabetes on cardiac structure and function

artículo científico publicado en 2016

Impaired incretin-induced amplification of insulin secretion after glucose homeostatic dysregulation in healthy subjects.

artículo científico publicado en 2012

Impaired regulation of the incretin effect in patients with type 2 diabetes

artículo científico publicado en 2011

Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes

artículo científico publicado en 2010

Increased expression of glucagon-like peptide-1 receptors in psoriasis plaques

artículo científico publicado en 2013

Increased postprandial GIP and glucagon responses, but unaltered GLP-1 response after intervention with steroid hormone, relative physical inactivity, and high-calorie diet in healthy subjects

artículo científico publicado en 2010

Increased postprandial responses of GLP-1 and GIP in patients with chronic pancreatitis and steatorrhea following pancreatic enzyme substitution

article

Incretin effect and glucagon responses to oral and intravenous glucose in patients with maturity-onset diabetes of the young--type 2 and type 3.

artículo científico publicado en 2014

Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes - a review

artículo científico publicado en 2010

Incretin-based therapies: viewpoints on the way to consensus

artículo científico publicado en 2009

Incretin-based therapy of type 2 diabetes mellitus

scientific article published on February 2009

Influence of gastrointestinal factors on glucose metabolism in patients with cirrhosis

artículo científico publicado en 2015

Is glucagon-like peptide-1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?

artículo científico publicado en 2018

Is the current therapeutic armamentarium in diabetes enough to control the epidemic and its consequences? What are the current shortcomings?

scientific article published on 20 June 2009

Liraglutide for the Treatment of Antipsychotic Drug-Induced Weight Gain-Reply

artículo científico publicado en 2017

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes

artículo científico publicado en 2007

Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus

artículo científico publicado en 2007

Lixisenatide for type 2 diabetes mellitus

scientific article published on 11 March 2011

Long-acting GLP-1 analogs for the treatment of type 2 diabetes mellitus

artículo científico publicado en 2008

Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes

artículo científico publicado en 2011

Mathematical Modelling of Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide-1 following Ingestion of Glucose

artículo científico publicado en 2017

Mechanisms of the incretin effect in subjects with normal glucose tolerance and patients with type 2 diabetes

artículo científico publicado en 2013

Metformin-associated risk of acute dialysis in patients with type 2 diabetes: A nationwide cohort study

artículo científico publicado en 2016

Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes

artículo científico publicado en 2018

Neuroprotective Mechanisms of Glucagon-like Peptide-1-based Therapies in Ischaemic Stroke: A Systematic Review based on Pre-Clinical Studies

artículo científico publicado en 2018

No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes

scientific article published on 16 January 2020

No changes in levels of bone formation and resorption markers following a broad-spectrum antibiotic course

artículo científico publicado en 2018

No hypoglycemia after subcutaneous administration of glucagon-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitis

artículo científico publicado en 2003

Nonalcoholic Fatty Liver Disease Is Prevalent in Women With Prior Gestational Diabetes Mellitus and Independently Associated With Insulin Resistance and Waist Circumference.

artículo científico publicado en 2016

Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in young men with low birth weight

artículo científico publicado en 2005

Normal secretion of the incretin hormones glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 during gestational diabetes mellitus

artículo científico publicado en 2007

On the role of gallbladder emptying and incretin hormones for nutrient-mediated TSH suppression in patients with type 2 diabetes

artículo científico publicado en 2014

One Year's Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial

artículo científico publicado en 2020

Oxyntomodulin Identified as a Marker of Type 2 Diabetes and Gastric Bypass Surgery by Mass-spectrometry Based Profiling of Human Plasma

artículo científico publicado en 2016

Pancreatic polypeptide responses to isoglycemic oral and intravenous glucose in humans with and without intact vagal innervation.

artículo científico publicado en 2015

Patient preferences for diabetes management among people with type 2 diabetes in Denmark - a discrete choice experiment

artículo científico publicado en 2011

Patients with psoriasis are insulin resistant

artículo científico publicado en 2015

Perceptions of diabetes control among people with type 2 diabetes treated with basal insulin in Sweden, Switzerland, and the United Kingdom

artículo científico publicado en 2016

Perceptions of diabetes control among physicians and people with type 2 diabetes uncontrolled on basal insulin in Sweden, Switzerland, and the United Kingdom

artículo científico publicado en 2016

Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake

artículo científico publicado en 2006

Postprandial Plasma Concentrations of Individual Bile Acids and FGF-19 in Patients With Type 2 Diabetes.

artículo científico publicado en 2016

Postprandial gallbladder emptying in patients with type 2 diabetes: potential implications for bile-induced secretion of glucagon-like peptide 1.

artículo científico publicado en 2014

Postprandial gut hormone responses and glucose metabolism in cholecystectomized patients

artículo científico publicado en 2012

Postprandial incretin and islet hormone responses and dipeptidyl-peptidase 4 enzymatic activity in patients with maturity onset diabetes of the young

artículo científico publicado en 2015

Presence of micro- and macroalbuminuria and the association with cardiac mechanics in patients with type 2 diabetes

artículo científico publicado en 2017

Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus

artículo científico publicado en 2009

Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial.

artículo científico publicado en 2018

Reduced Incretin Effect in Type 2 Diabetes

article by Filip K. Knop et al published 18 May 2007 in Diabetes

Risk stratification by endocrinologists of patients with type 2 diabetes in a Danish specialised outpatient clinic: a cross-sectional study

artículo científico publicado en 2016

Role of gastrointestinal hormones in postprandial reduction of bone resorption

artículo científico publicado en 2003

Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes: systematic review and meta-analysis of clinical studies

artículo científico publicado en 2013

Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk

artículo científico publicado en 2020

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

artículo científico publicado en 2016

Semaglutide improves health-related quality of life vs placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6)

artículo científico publicado en 2020

Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy

artículo científico publicado en 2017

Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men without Diabetes

artículo científico publicado en 2019

Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals

artículo científico publicado en 2019

Single-Dose Metformin Enhances Bile Acid-Induced Glucagon-Like Peptide-1 Secretion in Patients With Type 2 Diabetes

artículo científico publicado en 2017

Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans

artículo científico publicado en 2014

Sustained weight loss after treatment with a glucagon-like peptide-1 receptor agonist in an obese patient with schizophrenia and type 2 diabetes

artículo científico publicado en 2013

The GLP-1 receptor agonist lixisenatide reduces postprandial glucose in patients with diabetes secondary to total pancreatectomy: a randomised, placebo-controlled, double-blinded crossover trial

artículo científico publicado en 2020

The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes

artículo científico publicado en 2018

The bile acid-sequestering resin sevelamer eliminates the acute GLP-1 stimulatory effect of endogenously released bile acids in patients with type 2 diabetes

artículo científico publicado en 2017

The effect of a glucagon-like peptide-1 receptor agonist on glucose tolerance in women with previous gestational diabetes mellitus: protocol for an investigator-initiated, randomised, placebo-controlled, double-blinded, parallel intervention trial

artículo científico publicado en 2013

The effect of empagliflozin on oxidative nucleic acid modifications in patients with type 2 diabetes: protocol for a randomised, double-blinded, placebo-controlled trial

artículo científico publicado en 2017

The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty

artículo científico publicado en 2013

The effect of glucagon-like peptide 1 on cardiovascular risk

artículo científico

The effects of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: protocol for a systematic review with meta-analysis of randomised trials

artículo científico publicado en 2014

The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects

artículo científico publicado en 2006

The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action

artículo científico publicado en 2010

The impact of EndoBarrier gastrointestinal liner in obese patients with normal glucose tolerance and in patients with type 2 diabetes

artículo científico publicado en 2016

The incretin system and its role in type 2 diabetes mellitus

artículo científico publicado en 2008

The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance

artículo científico publicado en 2007

The role of efferent cholinergic transmission for the insulinotropic and glucagonostatic effects of GLP-1.

artículo científico publicado en 2015

The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes.

artículo científico publicado en 2011

The spectrum of antidiabetic actions of GLP-1 in patients with diabetes

artículo científico publicado en 2009

The use of double-balloon enteroscopy in retrieving mucosal biopsies from the entire human gastrointestinal tract

artículo científico publicado en 2014

Therapy: Liraglutide - preventing or postponing T2DM diagnosis?

artículo científico publicado en 2017

Trends in One-Year Outcomes of Dialysis-Requiring Acute Kidney Injury in Denmark 2005-2012: A Population-Based Nationwide Study

artículo científico publicado en 2016

Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone

artículo científico publicado en 2016

Typical Danish Caucasian type 2 diabetic patients do not commonly carry genetic variants in GIP and GLP-1 encoding regions of the proGIP and proglucagon genes

artículo científico publicado en 2004

Unprecedented high insulin secretion in a healthy human subject after intravenous glucagon-like peptide-1: a case report

artículo científico publicado en 2014

Women with prior gestational diabetes mellitus and prediabetes are characterised by a decreased incretin effect

artículo científico publicado en 2017

[Metformin is a possible glucagon-like peptide 1 stimulator]. ⬇️

artículo científico publicado en 2018

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda